B3 Therapeutics

B3 Therapeutics is a Yale University spinout developing a novel polymeric nanoparticle platform designed to bypass the blood-brain barrier (BBB) for the treatment of primary central nervous system (CNS) tumors and brain metastases. The company's technology utilizes sustained-release nanoparticles that can be delivered directly into the cerebrospinal fluid (CSF) via intrathecal infusion or convection-enhanced delivery (CED), ensuring broad distribution and prolonged retention within the CNS. B3's approach is versatile, capable of encapsulating various therapeutic payloads including small molecules and nucleic acids, such as antisense oligonucleotides. Its lead program focuses on delivering DNA repair inhibitors, such as PARP inhibitors, to treat aggressive brain cancers like medulloblastoma and glioblastoma while minimizing systemic toxicity.